Internuclear ophthalmoplegia

Summary

Internuclear ophthalmoplegia (MONDO:0003417) is a disease and 5 clinical trials. Top therapeutic interventions include clemastine and dalfampridine. A subtype of ophthalmoplegia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	internuclear ophthalmoplegia
Mondo ID	MONDO:0003417
DOID	DOID:538
ICD-10-CM	H51.2
ICD-11	377040542
SNOMED CT	49823009
UMLS	C0152134
MedGen	101820
Is cancer (heuristic)	no

Disease family

This is a subtype of ophthalmoplegia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › ocular motility disease › ophthalmoplegia › internuclear ophthalmoplegia

Related subtypes (2): exophthalmic ophthalmoplegia, progressive external ophthalmoplegia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05338450	PHASE3	TERMINATED	Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
NCT02391961	PHASE2	COMPLETED	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
NCT06417216	Not specified	RECRUITING	Head-Cancelled Virtual Reality for Ocular Cranial Nerve Palsies
NCT06629155	Not specified	NOT_YET_RECRUITING	Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests
NCT07560995	Not specified	NOT_YET_RECRUITING	Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLEMASTINE	4	3
DALFAMPRIDINE	4	1